These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20038729)

  • 1. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
    Shen L; Kantarjian H; Guo Y; Lin E; Shan J; Huang X; Berry D; Ahmed S; Zhu W; Pierce S; Kondo Y; Oki Y; Jelinek J; Saba H; Estey E; Issa JP
    J Clin Oncol; 2010 Feb; 28(4):605-13. PubMed ID: 20038729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome.
    Wang H; Zhang TT; Jin S; Liu H; Zhang X; Ruan CG; Wu DP; Han Y; Wang XQ
    Clin Epigenetics; 2017; 9():91. PubMed ID: 28861128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
    Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
    Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes.
    Poloni A; Goteri G; Zizzi A; Serrani F; Trappolini S; Costantini B; Mariani M; Olivieri A; Catarini M; Centurioni R; Alesiani F; Giantomassi F; Stramazzotti D; Biagetti S; Alfonsi S; Berardinelli E; Leoni P
    Eur J Haematol; 2013 Sep; 91(3):219-227. PubMed ID: 23679560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.
    Lin J; Wang YL; Qian J; Yao DM; Zhu ZH; Qian Z; Xu WR
    Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.
    Fan R; Zhang LY; Wang H; Yang B; Han T; Zhao XL; Wang W; Wang XQ; Lin GW
    Tohoku J Exp Med; 2012 Jun; 227(2):119-28. PubMed ID: 22706399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression.
    Zhao X; Yang F; Li S; Liu M; Ying S; Jia X; Wang X
    Br J Haematol; 2014 Jun; 165(5):649-58. PubMed ID: 24601943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
    Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
    Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberration of p73 promoter methylation in de novo myelodysplastic syndrome.
    Zhao Y; Gu S; Guo J; Zhang Z; Zhang X; Li X; Chang C
    Hematology; 2012 Sep; 17(5):275-82. PubMed ID: 22971533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
    Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
    Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
    Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of hypermethylation of DLC-1 gene in myelodysplastic syndrome patients and effects of decitabine on DLC-1 gene expression].
    Fu HY; Zhou HR; Yan JG; Chen CJ; Shen JZ
    Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):412-417. PubMed ID: 28219126
    [No Abstract]   [Full Text] [Related]  

  • 13. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
    Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
    Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
    Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
    Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
    Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.